Santhera Finalizes Vamorolone Filings And Now Seeks Funds
Seeking Priority Review For DMD Drug
The Swiss biotech is hoping that its Duchenne muscular dystrophy prospect, vamorolone, will get on the FDA fast track to approval but acknowledges that getting more funds is an urgent priority to prepare for a potential US launch.
